medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Prevalence of HR-HPV associated with cervical pre-cancerous lesions in Eastern-Province, Saudi Arabia

Haitham Kussaibi MD [1*], Reem Al Dossary MD [2], Ayesha Badar MD [1], Aroub Omar Muammar [3], Raghad Ibrahim Aljohani [3]

[1] Department of Pathology, College of Medicine, Imam Abdulrahman Bin Faisal University (IAU), Dammam, Saudi Arabia.

[2] Department of Microbiology, College of Medicine, Imam Abdulrahman Bin Faisal University (IAU), Dammam, Saudi Arabia.

[3] College of Medicine, Imam Abdulrahman Bin Faisal University (IAU), Dammam, Saudi Arabia.

***Corresponding author:**

Dr. Haitham KUSSAIBI

Assistant Professor

Department of Pathology

College of Medicine

Imam Abdulrahman Bin Faisal University (IAU)

Dammam, Saudi Arabia

Tel: +966554310433

E-mail: hkussaibi@iau.edu.sa

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

Objective: High-risk human papilloma virus (HR-HPV) is found to be responsible for 4.5% of all cancer, mainly, cervical cancer. The prevalence of HR-HPV and its significant association with cervical lesions are not well-known in Saudi Arabia. We aim here, to disclose the distribution of HR-HPV genotypes and correlate its association with cervical lesions which could help in customizing regional-specific vaccine-combinations and screening programs.

Methods: Over 6 years (2013 - 2018), 5091 Papanicolaou (Pap) smears results along with HR-HPV test results (whenever done), were collected from the King Fahd University Hospital (KFHU) Information System, in addition to the patients' age and nationality. Statistical analysis was performed using SPSS IBM.

Results: Out of 5091 Pap smears, only 1.89% (n=96) were abnormal; 0.18% (n=9) were malignant (7 SCC and 2 adenocarcinomas) and 1.7% (n=87) showed pre-cancerous lesions (44 ASCUS, 17 LSIL, 12 HSIL, and 14 AGC/AGUS). Out of 170 patients co-tested for HR-HPV, only 13.5% (n=23) had positive results (5 cases were positive for HR-HPV16, 1 case was positive for both HR-HPV16&18 and the remaining 17 cases were positive for HR-HPV other than 16/18). HR-HPV findings showed a significant correlation with the Pap smear results (P-value 0.000), however, it didn't show any significant correlation with the patients' age and/or nationality.

Discussion: Our study showed a unique distribution of HR-HPV genotypes, distinguished from the international distribution, which reflects a different geographical representation of infection patterns. Furthermore, the high association of normal Pap smears with HR-HPV highlights the need, along with Pap smear, for HR-HPV genotype tests for all women at risk.

Word count: 2589

Keywords: Squamous Intraepithelial Lesions of the Cervix, Human Papillomavirus DNA Tests, Papillomavirus Infections, Papillomavirus vaccines, Human Papillomavirus genotype, cervical precancerous lesions

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

INTRODUCTION

Human papillomaviruses (HPV) are a group of more than a hundred viruses associated with a wide range of mucocutaneous manifestation ranging from benign warts, affecting multiple anatomical sites, to potentially malignant and malignant anogenital and oropharyngeal lesions [1]. HPV is found to be responsible for 4.5% of all cancer worldwide [2]. In addition to cervical cancer, which accounts for 83% of HPV associated cancer, HPV is also detected in penile, vulvar, vaginal, anal and oropharyngeal cancer [2].

The determinant of the progression of HPV associated lesions from benign to malignant lesions includes the HPV type (genotype), HPV viral load [3] and HPV persistence [4]. Up to date, 14 types of HPV, also known as high risk (HR) HPV types, are known carcinogens and they include HPV type (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) [2], and persistence implies the detection of high-risk type for more than 6-12 months in cervical samples [5] since the majority of viral infections are cleaned in 1-1.5 year [3]. Studies on HPV viral load showed that the higher the viral load, the higher the progression to cancer will be [6].

Globally, the prevalence of HPV infection in women with normal Pap smear is 11-12% [7, 8] and it varies with geographical location, and socioeconomic status with the highest percentage in the Caribbean (35.4 %) and lowest in Western Asia (1.7%). Furthermore, female age and degree of cervical pathological changes affect the prevalence of HPV detection. Of all HPV types, the most detected are HPV-16 (3.2%), HPV-18 (1.4%), HPV-52 (0.9%), HPV-31 (0.8%) and HPV-58 (0.7%).

Due-to the high burden of the virus and its associated high morbidity and mortality, prevention of HPV related cervical cancer, is implemented at multiple levels starting from vaccination, to screening to early diagnosis and management [9].

Currently, there are three vaccines that are FDA approved and they include 2, 4, and 9 valent vaccines (2vHPV (Cervarix), 4vHPV (Gardasil), 9vHPV(gardasil9)) [10, 11]. HPV vaccines are made by recombinant DNA technology. The 2vHPV contains HPV 16, and 18, and the addition of HPV6 and 11, the causative agent of an anogenital wart, makes the 4vHPVvaccine. While, the 9vHPV vaccine includes all types included in 4vHPV in addition to HPV31, 33, 45, 52, and 58. These vaccines are recommended for females and males aged 11 - 26 years [11, 12].

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

For a screening purpose, a combination of cervical cytological evaluation (Pap smear) and DNA testing for human papillomavirus are currently employed and it is the preferred modalities to clinically segregate low-grade squamous intraepithelial lesion (LSIL) from the high-grade squamous intraepithelial lesion (HSIL) and squamous cell carcinoma (SCC) [13]. Clinical outcome of patients having ASCUS (atypical squamous cells of undetermined significance) and LSIL is documented to be similar and their treatment options are controversial [14]. Seventy percent of ASCUS and low-grade lesions show spontaneous regression [15]. ASCUS or LSIL progressing to HSIL is still debatable and yet remains a diagnostic and clinical challenge for cytopathologists, clinicians and patients. Performing colposcopy and biopsy for all such patients will markedly increase the rates of these procedures with a negative impact of patient's physical and psychological health, especially for those patients whose lesions are not prone to develop into HSIL. Consequently, an additional triage comprising HR-HPV PCR detection is recommended for all women with ASCUS/LSIL [16, 17].

HR-HPV DNA testing has been shown in trials to be more sensitive than cervical cytology in the detection of intraepithelial lesions [18]. This increased sensitivity can safely lead to more spaced apart screening time intervals [19-21].

The prevalence and genotype of HR-HPV infection detected in women with normal or abnormal cytology (ASCUS, LSIL, and HSIL) are so far unknown (according to "HPV and related diseases report" in Saudi Arabia published by the "HPV information center" on December 2018) [22, 23]. Our study aims to highlight for the first time, the prevalence and genotype distribution of HR-HPV infection and its association with cervical cancer and precancerous lesions which provide recommendations for a vaccine-combination customized to the population in the Eastern-Province and other areas in Saudi Arabia.

METHODS

Study design:

Retrospective cross-sectional study to determine the prevalence and genotype distribution of HR-HPV and its association with cervical cancer and precancerous lesions in patients attending obstetrics and gynecology (OB-GYN) clinic at KFHU in the Eastern Province, Saudi Arabia for 6 years period (2013-2018). For routine cervical cancer screening, Pap smear is done for all married women aged 21-65 years, every 3 years without or with HR-HPV

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

molecular testing (for patients at high risk). Furthermore, HR-HPV molecular testing is done for all patients showing ASCUS on cytological examination (as per CAP recommendation).

Cytological examination:

Cervical Pap smears were collected at obstetrics and gynecology clinics in a commercially available liquid fixative vial (SurePath liquid-based pap, BD, USA) to be processed in a semi-automated machine (The PrepStain System) which is a liquid-based thin-layer cell preparation processor. The PrepStain system produces the SurePath slides for microscopic examination by a pathologist and reported according to "The Bethesda System".

HR-HPV detection

As per our college of American pathologist (CAP)-accredited Lab policy, all cervical samples with Pap smear reported as ASCUS should be sent for HR-HPV testing. Furthermore, some cervical samples for patients at high risk were submitted for HR-HPV molecular testing, directly from Ob/Gyne clinics, in parallel to Pap smear. In both ways, Samples were preserved using the same vial "SurePath liquid-based Pap" mentioned above. Detection of HR-HPV was done using Xpert HPV assay which is a fully automated multiplex qualitative real-time polymerase chain reaction (PCR) using Genexpert by CEPHEID. This test detects and identifies all the 14 HR-HPV types. The results are reported as negative or positive (HPV16, HPV18 and/or other HR HPV types without further specification).

Statistical analysis:

All Statistical analysis was performed using SPSS IBM with significant correlation on P-value 0.05 or less.

RESULTS

1. Prevalence of cervical cancer and pre-cancer lesions in women attending OBGYNE clinic at KFHU in the eastern province of KSA between 2013-2018:

Over the 6 years study period, 5091 Pap smears were tested, only 96 (1.89%) were abnormal, and the remaining 4995 were normal (Figure 1.). Out of the 96 abnormal Pap smears, 9 (0.18%) were malignant (7 SCC and 2 adenocarcinomas) and 87 (1.7%) showed pre-cancerous cervical lesions in the form of ASCUS, LSIL, HSIL, or AGC/AGUS (table 1, Figure 1 and 2).

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Among all 96 patients with abnormal Pap smears, only 30 (31.25%) patients underwent cervical histology examination, among them, only 15 patients showed abnormal histology (malignant or pre-malignant), the remaining patients had either cervicitis or benign polyps by histological examination.

Table 1 Pap smear results for women attending OBGYNE clinic, KFHU between 2013-2018:

Pap smear results	Number	Percentage (%)
ASCUS/ ASC-H	44	0.86
LSIL	17	0.33
HSIL	12	0.24
AGC/AGUS	14	0.27
Squamous cell carcinoma	7	0.14
Adenocarcinoma	2	0.04
Normal	4995	98.11
Total Pap smear	5091	100

2. Results of patients co-tested for Pap smear and HR-HPV genotypes (between 2013-2018):

Over the 6 years study period, only 170 women were co-investigated for HR-HPV genotypes in addition to Pap smear (patients at high risk of infection and those who had ASCUS on Pap smear). Out of them, only 13.5% (n=23) cases were positive for HR-HPV, while the remaining 86.5% (n=147) cases were negative (HR-HPV not detected). Among the 23 patients positive for HR-HPV, the most detected genotypes were “HR-HPV other than 16/18” in 73.91% (n=17) patients, followed by HPV16 in 26.09% (n=6) patients, and finally HPV18 in 4.35% (n=1) patient. Almost, a similar distribution of HR-HPV types was seen in patients with normal and abnormal Pap smear. Among the 86.5% (n=147) patients with negative HR-HPV, the majority 70.59 % (n=120) had normal Pap smear, while the remaining 15.88% (n=27) had abnormal Pap smear (6 with LSIL and 21 with ASCUS). On the other hand, among the 13.5% (n=23) patients positive for HR-HPV, 6.47% (n=11) had normal Pap smear, while 7.06% (n=12) patients had abnormal Pap smear (4 ASCUS, 6 LSIL and 2 HSIL) **(Table 2)**.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2 Results of 170 patients co-tested for Pap smear and HR-HPV:

HR-HPV genotyped (170 patients)	Normal Pap smear 77.07% (n=131)	Abnormal Pap smear 22.93% (n=39)		
		ASCUS (n=25)	LSIL (n=12)	HSIL (n=2)
Not detected 86.5% (n=147)	81.6% (n=120)	18.3% (n=27)		
		21	6	0
Total detected 13.5% (n=23)	47.8% (n=11)	52.2% (n=12)		
		4	6	2
HPV16 (5 cases)	3	0	2	0
HPV 16&18 (1 case)	0	0	1	0
HR-HPV other than 16/18 (17 cases)	8	4	3	2

3. Correlation of age, nationality and cytology examination with HPV status:

There was a significant correlation between Pap smears findings and HR-HPV status and vice versa (P-value 0.000). Concerning the age distribution, our data showed that all the HPV16 and/or HPV18 patients were younger than 40 years old, while, the cases positive for HR-HPV other than 16/18 showed wide age distribution (21 - >61), however, there was no significant correlation between HR-HPV status and age.

Considering that most of our patients, in the study, are Saudis, there was no significant correlation between HR-HPV status and patients' nationalities.

DISCUSSION

This 6-year retrospective study conducted to disclose the association of different HR-HPV types with abnormal Pap smears (pre-cancerous and cancerous cervical lesions), included a total of 5091 cervical Pap smears, the primary cervical cancer screening tool used in our center. Only 1.89% (n=96) Pap smears were abnormal. On the other hand, only 170 patients were co-tested for HR-HPV in addition to Pap smear, among them, only 22.94% (n=39) had abnormal Pap smear 14.70% (n=25) diagnosed as ASCUS, 7.05% (n=12) as LSIL and 1.17% (n=2) as HSIL. Among those 22.94% (n=39) patients with abnormal Pap smear, HR-HPV was detected in merely 7.05% (n=12) patients

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

including 2.35% (n=4) had ASCUS, 3.53% (n=6) had LSIL and 1.18% (n=2) had HSIL. The remaining 15.88% (n=27) patients with abnormal Pap smear showed negative results for HR-HPV (table 2).

HPV16, which is the most common type seen in ASCUS in many studies, has not been detected in any of the 25 cases of ASCUS in our study, however, only 4 (16.66%) out of the 25 ASCUS cases were positive for HR-HPV other than 16/18. In an Iranian study conducted by Karimi-Zarchi et al in 2015, out of 180 cases of ACSUS evaluated, an overall HR-HPV was seen in 58 (32.22%) with HPV16 seen in 46 (25.5%). This was followed by HPV18 in 2 (1.11%) and other HR-HPV in 10 (5.5%) [24]. A study by Clifford et al, documented HPV16 in ASCUS to be 31% [25]. A Turkish study reported it to be 35% (n=33/94)[26]. Besides the variation in the types of HPV, the frequency of HPV positivity in ASCUS was also in a much lower range in our study than in other reported studies. These variations are highly reflective of different geographical representations of infection patterns. These also warrant a more elaborate and in-depth analysis of infection demographics, so that specific screening and follow up strategies could be developed, tailored to the endogenous regional needs which are so far highly deficient in this region.

In our study, a total of 12 cases of LSIL retrieved, 50% (n=6) were positive for HR-HPV. This is in stark contrast to a Chinese study by Zheng et al. who reported 75.8% of women with LSIL to be HR-HPV positive with HPV positivity rates declining with increasing age except in patients older than 60 years [27]. A Turkish study reported it to be 62% (n=18/29) [26]. Regarding HSIL, from an overall 12 cases, 16.66% (n=2) were seen to be HR-HPV positive. In the Turkish study, it was reported to be 83% (n=5/6) [26].

Again, the local figures for the frequency of HR-HPV in LSIL and HSIL show marked fluctuations from other international studies. Our limited sample size raises two issues. First, in our center, we do not have an organized, implemented screening program so most of the cases coming to gyne OPD, were not tested for HR-HPV, and these figures could be just reflecting an iceberg with completely unfathomed depths and boundaries. This highlights the need for a more vigilant screening program so the missed cases can be picked up and a true reflection of infection characteristics gets unraveled. Additionally, as pointed out earlier too, the frequency pattern with its limitation is still highlighting our regional infection characteristics.

Abnormal Pap cytology with negative HR-HPV was seen in 21(12.35%) of ASCUS. This could be attributed to the overdiagnosis of ASCUS or due to the negative predictive value of HR-HPV testing.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Regarding Atypical Squamous Cells, (ASC) overdiagnosis, this diagnostic entity is yet controversial to the end-users, the pathologists and clinicians, with no accompanying definite histological cervical lesion. It just signifies that the cervix might or might not have an associated pathology. Bethesda 2016 Committee recommended strict criteria for the ASC category, however, its overuse still high in many laboratories. Gupta et al reported ASC cytological diagnosis followed by a negative cervical biopsy diagnosis in 199 cases. They reviewed the initial cytological diagnosis and concluded that an initial over-diagnosis of ASC could be attributed to the presence of perimenopausal cells (17.6%), atypia attributable to reproductive tract infection in (14.6%) smears, hormonal induced alterations (8.5%), drying artifacts (3.5%) and immature metaplastic cell (2%) [28]. Many of these cases are not associated with significant lesions, which leads to many unnecessary colposcopies, biopsies, HPV typing or even repeated Pap tests.

Many studies showed that the majority of LSIL is associated with evidence of HPV infection (55% to 89% of LSIL are positive HR-HPV). However, in this study, negative HR-HPV was seen in 6 (50%) of LSIL cases. Barron et al reported a follow up of 468 patients from a total of 608 patients who had an initial diagnosis of LSIL with negative HPV [29]. HSIL was seen in 3% (n=14 cases) and LSIL in 39.3 % (n=184). No case of cervical carcinoma was seen. Bosquet et al in a retrospective study conducted in a period from 2003 to 2015 constituting 609 cases, reported that 12% of HSIL was negative for HPV [30]. In our set up a stricter follow up of LSIL cases with negative HR-HPV needs to be developed.

Out of a total of 170 cervical cytological cases tested for HR-HPV, a major proportion comprising 147 cases (86.47%) cases were negative for HR-HPV. These negative cases combined with normal cytology were seen in 120 (70.59%) cases.

Regarding HR-HPV positive cases with normal cytology, it was detected in 6.4% (n=11). This prevalence is higher than reported in a regional Kuwaiti study in which 2.3 % (n=71/3011) of cases showed HR-HPV positivity in normal cervical smears (2.73% Kuwaiti and 1.63% non□Kuwaitis) [31]. A study in Asia and Europe showed the variability of normal Pap smear associated with HPV infection, ranging from 3.8% in Thailand, 2.9% in Spain, to 1.6% in Vietnam [29]. A large cohort Dutch study (Population-Based Screening Study Amsterdam) reported it to be 3.8 % (n=724/19, 286). However, our prevalence is far less than documented in a Turkish study which stated it to be 17.41% (n=35/201) [26]. Meta-analysis (PCR based) worldwide studies showed that HPV in patients with normal Pap smear is 10% [32]. Our prevalence pattern of 6.4% HR-HPV in normal cervical smears is reflective of

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

indigenous regional infection prevalence characteristics which have so far not been explored and fathomed. Our sample size in which the HR-HPV testing was done was small but still, it forms a nidus on which more extensive regional studies can be based.

The presence of HR-HPV in normal cervical smears highlights the need for an active screening program. A patient ≥30 years with a positive HPV and negative cytology is at higher risk of cervical cancer. The management of this category may include repeat HPV and cytology co-testing at 12 months. If the patient is still positive for HPV, colposcopy needs to be performed immediately [26].

A decreased prevalence of HR-HPV in cases of ASCUS, LSIL, and HSIL in our set of cases along with a complete absence of HPV 16 and 18 in ASCUS is in stark contrast to other regional and international studies. This variation is highly reflective of different geographical representations of infection patterns. Additionally, the presence of HR-HPV is cases with normal cytological smears highlights the need for an active screening program tailored specifically to our endogenous, local, regional needs.

Acknowledgments:

This work was funded By DSR at Imam Abdulrahman Bin Faisal University (Project number 201815).

The authors are grateful to Dr. Ahlam Alghamdi, Consultant Obgyne and Mrs. Raeda Alkhateeb, Cyto Lab specialist at King Fahd Hospital of the University for their valuable contribution.

Conflict of Interest:

The authors declare no conflict of interest in the paper.

Ethical approval

Ethical approval was obtained from the “Standing Committee on Research Ethics on Living Creatures” (SCRELC) at Imam Abdulrahman Bin Faisal University with IRB-2018-01-157.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

REFERENCES

1. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best practice & research Clinical obstetrics & gynaecology. 2018;47:14-26.
2. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664-70.
3. de Sanjose S, Brotons M, Pavon MA. The natural history of human papillomavirus infection. Best practice & research Clinical obstetrics & gynaecology. 2018;47:2-13.
4. Crow JM. HPV: The global burden. Nature. 2012;488(7413):S2-3.
5. Syrjanen K. Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV 16/18) prophylactic HPV vaccines. European journal of gynaecological oncology. 2011;32(1):17-33.
6. Zhao X, Zhao S, Hu S, Zhao K, Zhang Q, Zhang X, et al. Role of Human Papillomavirus DNA Load in Predicting the Long-term Risk of Cervical Cancer: A 15-Year Prospective Cohort Study in China. The Journal of infectious diseases. 2019;219(2):215-22.
7. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12-23.
8. Keinan Boker L, Twig G, Klaitman-Meir V, Derazne E, Shina A, Levine H, et al. Adolescent characteristics and incidence of pre-malignant disease and invasive tumors of the cervix. Int J Gynecol Cancer. 2020.
9. Gultekin M, Ramirez PT, Broutet N, Hutubessy R. World Health Organization call for action to eliminate cervical cancer globally. Int J Gynecol Cancer. 2020.
10. de Oliveira CM, Fregnani J, Villa LL. HPV Vaccine: Updates and Highlights. Acta cytologica. 2019;63(2):159-68.
11. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports. 2014;63(Rr-05):1-30.
12. Petrosky E, Bocchini JA, Jr., Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-4.
13. Li T, Li Y, Yang GX, Shi P, Sun XY, Yang Y, et al. Diagnostic value of combination of HPV testing and cytology as compared to isolated cytology in screening cervical cancer: A meta-analysis. Journal of cancer research and therapeutics. 2016;12(1):283-9.
14. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. Journal of lower genital tract disease. 2013;17(5 Suppl 1):S43-9.
15. Alanen KW, Elit LM, Molinaro PA, McLachlin CM. Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Cancer. 1998;84(1):5-10.
16. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88-99.
17. Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf JJ, Da Silva D, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology : official journal of the British Society for Clinical Cytology. 2008;19(6):342-54.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

18. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet (London, England). 2014;383(9916):524-32.
19. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. European journal of cancer (Oxford, England : 1990). 2011;47(6):864-71.
20. Madom LM, Boardman LA. HPV testing and cervical cancer screening: recommendations and practice patterns. Medicine and health, Rhode Island. 2005;88(10):362-3.
21. Patnick J. Review of recommendations on cervical cancer screening in the European Union. Minerva ginecologica. 2003;55(4):293-5.
22. Anfinan NM. Physician's knowledge and opinions on human papillomavirus vaccination: a cross-sectional study, Saudi Arabia. BMC Health Serv Res. 2019;19(1):963.
23. Mousa M, Al-Amri SS, Degnah AA, Tolah AM, Abduljabbar HH, Oraif AM, et al. Prevalence of human papillomavirus in Jeddah, Saudi Arabia. Ann Saudi Med. 2019;39(6):403-9.
24. Karimi-Zarchi M, Tabatabaie A, Dehghani-Firoozabadi A, Shamsi F, Baghianimoghaddam M, Dargahi M, et al. The Most Common Type of HPV in Women with Atypical Squamous Cell of Undetermined Significance (ASCUS) in Pap Smear in Iran-Yazd. Int J Biomed Sci. 2015;11(4):173-5.
25. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1):63-73.
26. Beyazit F, Sılan F, Gencer M, Aydin B, Paksoy B, Unsal MA, et al. The prevelance of human papillomavirus (HPV) genotypes detected by PCR in women with normal and abnormal cervico-vaginal cytology. Ginekol Pol. 2018;89(2):62-7.
27. Zheng B, Yang H, Li Z, Wei G, You J, Liang X, et al. HPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China. J Cancer. 2017;8(13):2436-41.
28. Gupta S, Sodhani P. Reducing "atypical squamous cells" overdiagnosis on cervicovaginal smears by diligent cytology screening. Diagn Cytopathol. 2012;40(9):764-9.
29. Barron S, Austin RM, Li Z, Zhao C. Follow-up outcomes in a large cohort of patients with HPV-negative LSIL cervical screening test results. Am J Clin Pathol. 2015;143(4):485-91.
30. González-Bosquet E, Fernandez S, Sabra S, Lailla JM. Negative HPV testing among patients with biopsy-proven cervical intraepithelial neoplasia grade 2/3 or cervical cancer. Int J Gynaecol Obstet. 2017;136(2):229-31.
31. Al-Awadhi R, Chehadeh W, Kapila K. Prevalence of human papillomavirus among women with normal cervical cytology in Kuwait. J Med Virol. 2011;83(3):453-60.
32. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453-9.

medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037465; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 1: Prevalence of cervical cancer and precancerous lesions among women having PAP smear at KFHU in Saudi Arabia between 2013-2018



Figure 2: Frequency details of cervical cancers and precancerous lesions among the 96 abnormal Pap smears